Bio-Techne Corporation
Rank #217ValueTECH · Nasdaq · Healthcare
Bio-Techne Corporation (TECH) — Rank #217 by gross profitability (GP/assets 0.31) · ROE 8.6% · Piotroski F-Score 7 / 9.
As-of 2026-09-15 · CIK 0000842023 · all metrics point-in-time as of the filing date.
About
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide.
Show moreShow less
It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. Its Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014.
Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
- Industry
- Biotechnology
- Sector
- Healthcare
- State
- MN
- Filer Category
- Large accelerated filer
- Fiscal Year End
- June 30
- Website
- bio-techne.com
Price History
Company Snapshot
P/E and dividend yield are the primary valuation lenses for mature businesses.
Market Cap
$11.33B
P/E (annual)
62.3
P/S (annual)
9.3
P/B
5.4
P/OCF (annual)
38.8
Shareholder Yield
2.1%
Employees
3,000
Industry
Biotechnology
Exchange
Nasdaq
Signal Flags
Quality Profile
Profitability
1/1 passSafety
1/1 passCash Flow
3/3 passGrowth
1/2 passTerry Smith quality gate
Passes 3/5 Terry Smith thresholds1 of 5 threshold not computable from filed data.
What Growth Is Priced In
Implied revenue growth (10Y)
18.2%
The annual FCF growth rate today's price requires over a 10-year horizon (discount rate 10%, terminal growth 2.5%).
Buyback tailwind: -1.7% — per-share value needs a total required return of 16.5% once share-count change is priced in.
vs. own 6-year median revenue growth: 5.2%
priced above its own historyCost-of-equity sensitivity (implied growth at different discount rates)
r = 8%
13.3%
r = 10% (base)
18.2%
r = 12%
22.4%
Net debt / market cap: -2.3%
Valuation History
Current multiple vs historical range at each filing date. Band spans 25th-75th percentile.
P / E
Price / diluted EPS
P / S
Price / revenue per share
P / B
Price / book value per share
P / GP
Price / gross profit per share
P / FCF
Price / free cash flow per share
Dividend yield and payout ratio are the primary reads at this stage (trailing P/E — see valuation above).
Profitability
Gross profitability (GP / assets)
0.31
Primary signal (Novy-Marx).
73rd pctl of 34 SIC 28 peers
Return on equity
8.6%
Gross margin
65.8%
70th pctl of 34 SIC 28 peers
Revenue growth (YoY)
-0.4%
Gross margin improving
Margin trend vs prior year.
Operating Leverage
| 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|
| Revenue vs COGS | ||||
| Revenue vs OpEx | ||||
| Op. Income vs Revenue |
Growth
Revenue CAGR (3Y)
2.2%
Revenue CAGR (5Y)
5.5%
Earnings CAGR (3Y)
—
FCF CAGR (3Y)
—
Anti-fragile safety
Balance-sheet safety
Composite anti-fragile check.
Debt / equity
0.24
90th pctl of 31 SIC 28 peers (best = lowest)
Current ratio
4.55×
79th pctl of 34 SIC 28 peers
Quick ratio
2.95×
Net cash
$265.78M
Cash & equivalents minus total debt.
Cash-flow health
Free cash flow
$263.22M
Operating cash flow minus capex.
Positive free cash flow
FCF / net income
0.45
Cash-backing of earnings.
FCF/NI divergence
Unfavorable divergence (yellow flag).
Accruals healthy
Cash-backed earnings.
SBC / revenue
3.4%
Stock-based comp intensity.
Dividend safety
Composite score
3.0 / 5
Piotroski F-Score
F-Score
7 / 9
Fundamental-strength score (0-9).